Omeros FY2025 EPS Forecast Decreased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has lowered its FY2025 EPS estimates for Omeros to ($2.14) from ($2.04), while the consensus estimate stands at ($3.09) per share.
• Omeros stock has recently seen a 6.0% decline and currently trades at $3.59, with a market capitalization of $210.34 million.
• Analysts have mixed ratings on Omeros, with an average rating of "Moderate Buy" and a consensus price target of $18.00 for the stock.

Omeros Corporation (NASDAQ:OMER - Free Report) - Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Omeros in a note issued to investors on Wednesday, July 23rd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will post earnings per share of ($2.14) for the year, down from their previous forecast of ($2.04). The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros' FY2026 earnings at ($1.16) EPS.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Friday, May 16th. Wall Street Zen cut Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. D. Boral Capital reissued a "buy" rating and set a $36.00 price objective on shares of Omeros in a report on Friday. Finally, HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Stock Down 6.6%

OMER traded down $0.28 during trading on Friday, reaching $3.88. 976,946 shares of the company's stock were exchanged, compared to its average volume of 870,414. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The business has a 50 day moving average price of $3.38 and a 200 day moving average price of $6.24. The company has a market capitalization of $227.05 million, a P/E ratio of -1.46 and a beta of 2.16.

Hedge Funds Weigh In On Omeros

Several institutional investors and hedge funds have recently modified their holdings of OMER. Vanguard Group Inc. boosted its position in Omeros by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company's stock worth $26,610,000 after acquiring an additional 95,599 shares during the last quarter. Nomura Holdings Inc. boosted its position in Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock worth $7,383,000 after acquiring an additional 430,932 shares during the last quarter. Two Sigma Investments LP boosted its position in Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company's stock worth $1,610,000 after acquiring an additional 13,201 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Omeros by 2.2% during the 1st quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock worth $1,242,000 after acquiring an additional 3,321 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Omeros during the 4th quarter worth approximately $1,488,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.